711 uptown mall

VANCOUVER — Brayden Point scored twice and added two assists, and the Tampa Bay Lightning edged the Vancouver Canucks 3-2 on Sunday. Nikita Kucherov had a goal and two helpers for the Lightning (14-9-3), while Jake Guentzel put away the game winner on a power play late in the third period. Captain Quinn Hughes and Kiefer Sherwood found the back of the net for the Canucks (14-8-4), who fell to 4-6-3 at home. Tampa Bay's Andrei Vasilevskiy stopped 22 of the 24 shots he faced and Kevin Lankinen made 28 saves for Vancouver. TAKEAWAYS Canucks: Hughes took a stick to the face 55 seconds into the game, missed more than 11 minutes, then returned to open the scoring 16:08 into the first period. It was the 50th goal of the defenceman's career and extended his points streak to seven games with three goals and 10 assists across the stretch. Lightning: Kucherov, who returned to the lineup Sunday after missing two games with a lower-body injury, added another potent piece to Tampa's red-hot power play. The Lightning were 2-for-4 with the man advantage and scored a power-play goal for the sixth straight game. KEY MOMENT Tampa took the lead 6:29 into the second when Kucherov sliced a pass to Point at the bottom of the faceoff circle and the Lightning winger blasted it in past Lankinen for his 17th of the season. Kucherov put the visitors on the board just a minute and 49 seconds earlier. KEY STAT Point scored his league-leading 10th power-play goal of the season. He’s one away from becoming the third player to score 100 power-play goals for the Lightning UP NEXT Canucks: Continue a six-game homestand Tuesday against the St. Louis Blues. Lightning: Visit the Oilers in Edmonton on Tuesday. This report by The Canadian Press was first published Dec. 8, 2024. Gemma Karstens-Smith, The Canadian PressTikTok files legal challenge of federal government's shutdown order711 uptown mall 。

Spaghetti bolognese is a beloved dish in many UK homes, with each cook adding their unique twist to the recipe. However, Michelin-starred chef Paul Foster claims that we've all been overlooking a crucial ingredient - a breakfast staple you wouldn't typically associate with bolognese. The owner of the Michelin-starred Salt in Stratford-upon-Avon took to TikTok last year to share his secret. He asked his followers: "Are you adding milk to your bolognese? If not, why not? If you want the best results based on authenticity, then follow my method – [this is] how to cook bolognese properly." He proceeded to provide a detailed guide to his version of bolognese, stating: "This recipe is based on my culinary knowledge, my nostalgia and also my experiences with the original recipes in Bologna." He emphasised the importance of starting with a 'sofrito', a blend of finely diced onions, celery and peeled carrot. After preparing these ingredients, he added them to a pan of hot olive oil with a generous pinch of salt, cooking them gently for about three to four minutes without any colour, reports the Express . Next, add the chopped thyme and crushed garlic to the pan and cook for another two minutes without browning. Remove from heat and set aside. In the same pan, combine equal parts minced beef and pork, cooking on high heat while stirring continuously. Once browned, Paul suggests adding a full-bodied red wine and allowing the mixture to reduce. Stir in tomato puree, then reintroduce the pre-cooked vegetable mix, along with good quality tinned tomatoes and chicken stock. "It's going to be quite wet so you want to cook this gently for about three hours to reduce it and concentrate it so it becomes thick and glossy," Paul advised. He then revealed his secret ingredient: "Then in with the milk." "This gives it that creaminess without adding cream – honestly, this is a game changer. Stir that in for a while and then check it for seasoning."

Car burned after graffiti sprayed to 'strike fear'Researchers at Uppsala University and KTH Royal Institute of Technology have created an antibody that has the potential to treat a variety of cancers. Researchers were able to integrate three different functionalities in the antibody, which combined significantly increased the action of T cells on the cancer tumour. Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system (“3-in-1 design”) for personalised immunotherapy treatments. “We have been researching precision medicine for close to 15 years now, as well as how we can use antibodies to influence an important key protein (CD40) in the immune system. We can now show that our new antibody method works as precision medicine for cancer,” explains Sara Mangsbo, professor at the Department of Pharmacy at Uppsala University, who together with Johan Rockberg, professor at KTH Royal Institute of Technology, is the study’s lead author. The drug redirects the immune system to find and target specific mutations and gene changes that are only found in cancer cells, known as neoantigens. This is achieved by the new antibody both delivering the unique tumour-specific material directly to a particular type of immune cell and by stimulating this cell simultaneously, which then has the capacity to greatly enhance the T-cell response to the tumour. The results show that the method works in several ways. Not only does it activate the right type of immune cells in human blood samples, but animal models show that mice receiving the treatment had prolonged survival and, at higher doses, also save the mice from cancer, and that the method is safer than previous cancer treatments the researchers have studied. Customised precision medicines can be both costly and time-consuming to develop. “The advantage of our drug is that it is easy to produce on a larger scale , yet can be easily tailored to the patient’s disease or specific tumour. The medicine consists of two parts that are combined, a targeting bispecific antibody – which can be produced in large quantities in advance – and a custom peptide part, which is produced rapidly synthetically on a small scale for a desired type of cancer. Both in terms of production cost and the short time it takes to tailor a peptide to a new tumour, this increases availability and should make it quicker for patients to go from diagnosis to treatment,” explains Johan Rockberg, Professor at KTH Royal Institute of Technology. The aim of the study was to establish a more flexible, faster and safer treatment for cancer than those currently available. The study has already shown that the method has the potential to be customised for each patient, thereby strengthening the immune system against cancer. The next step is to use the fully optimised production process to manufacture the drug candidate for further safety studies and then start clinical trials in humans. (with inputs from ANI)

Mayor Olivia Chow’s city hall inconsistently addresses antisemitism in Toronto, according to complaintsMLB Rumors: Juan Soto Likely to Get Contract Offers This Week Amid Yankees, Mets Buzz